GlassScriptPhysician profile
Matthew A Hevey
NPI 1356769590
$7,678.69
in general payments reported to CMS, 2019-2025
17 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $134 · 2021: $164 · 2022: $653 · 2023: $5,472 · 2024: $437 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,750 · Food and Beverage: $1,539 · Travel and Lodging: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,750.00 |
| Food and Beverage | $1,538.92 |
| Travel and Lodging | $1,125.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,915.47 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $880.51 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $270.63 | 2019-2025 | Pifeltro, Zerbaxa, Recarbrio |
| Abbvie INC. | $184.88 | 2021-2024 | |
| Astellas Pharma US INC | $65.70 | 2023-2025 | Cresemba |
| Shionogi INC | $47.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $45.16 | 2023-2024 | Ultomiris, Soliris |
| Ferring Pharmaceuticals INC. | $44.15 | 2022-2023 | Rebyota |
| Janssen Biotech, INC. | $40.82 | 2019 | |
| La Jolla Pharmaceutical Company | $33.87 | 2021-2024 | Xerava |
| Tetraphase Pharmaceuticals, INC. | $33.45 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $21.22 | 2020 | |
| Insmed, INC. | $20.95 | 2024 | Arikayce |
| Melinta Therapeutics, LLC | $20.58 | 2022 | |
| Aimmune Therapeutics, INC. | $19.84 | 2025 | Vowst |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ossur Americas, INC. | $18.45 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hevey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.